Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey

ArticleAçık Erişim

Özet

Objective: The TURKMI registry is designed to provide insight into the characteristics, management from symptom onset to hospital discharge, and outcome of patients with acute myocardial infarction (MI) in Turkey. We report the baseline and clinical characteristics of the TURKMI population. Methods: The TURKMI study is a nation-wide registry that was conducted in 50 centers capable of percutaneous coronary intervention selected from each EuroStat NUTS region in Turkey according to population sampling weight, prioritized by the number of hospitals in each region. All consecutive patients with acute MI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018 and November 16, 2018. Results: A total of 1930 consecutive patients (mean age, 62.0±13.2 years; 26.1% female) with a diagnosis of acute MI were prospectively enrolled. More than half of the patients were diagnosed with non-ST elevation MI (61.9%), and 38.1% were diagnosed with ST elevation MI. Coronary angiography was performed in 93.7% and, percutaneous coronary intervention was performed in 73.2% of the study population. Fibrinolytic therapy was administered to 13 patients (0.018%). Aspirin was prescribed in 99.3% of the patients, and 94% were on dual antiplatelet therapy at the time of discharge. Beta blockers were prescribed in 85.0%, anti-lipid drugs in 96.3%, angiotensin converting enzyme inhibitors in 58.4%, and angiotensin receptor blockers in 7.9%. Comparison with European countries revealed that TURKMI patients experienced MI at younger ages compared with patients in France, Switzerland, and the United Kingdom. The most prevalent risk factors in the TURKMI population were hypercholesterolemia (60.2%), hypertension (49.5%), smoking (48.8%), and diabetes (37.9%). Conclusion: The nation-wide TURKMI registry revealed that hypercholesterolemia, hypertension, and smoking were the most prevalent risk factors. TURKMI patients were younger compared with patients in European Countries. The TURKMI registry also confirmed that current treatment guidelines are largely adopted into clinical cardiology practice in Turkey in terms of antiplatelet, anti-ischemic, and anti-lipid therapy. ©Copyright 2020 by Turkish Society of Cardiology

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/13600Resmi atıflarda kullanılan kalıcı adres
Tam Kayıt
AlanDeğerDil
dc.contributor.authorErol, Mustafa Kemal
dc.contributor.authorKayıkçıoğlu, Meral
dc.contributor.authorKılıçkap, Mustafa
dc.contributor.authorArın, Can Baba
dc.contributor.authorKurt, İbrahim Halil
dc.contributor.authorAktaş, İbrahim
dc.contributor.authorGüneş, Yılmaz
dc.contributor.authorÖzkan, Eyüp
dc.contributor.authorŞen, Taner
dc.contributor.authorİnce, Orhan
dc.contributor.authorÖrnek, Ender
dc.contributor.authorAsoğlu, Ramazan
dc.contributor.authorAladağ, Nesim
dc.contributor.authorZeybey, Utku
dc.contributor.authorSinan, Ümit Yaşar
dc.contributor.authorDural, Muhammet
dc.contributor.authorTüner, Haşim
dc.contributor.authorDoğan, Arda Can
dc.contributor.authorYenerçağ, Mustafa
dc.contributor.authorAkboğa, Mehmet Kadri
dc.contributor.authorDeveci, Onur Sinan
dc.contributor.authorSomuncu, Mustafa Umut
dc.contributor.authorInanir, Mehmet
dc.contributor.authorYalçin, Osman Yasin
dc.contributor.authorGenc, Omer
dc.contributor.authorYildirim, Abdullah
dc.contributor.authorInci, Sinan
dc.contributor.authorCetin, Mustafa
dc.contributor.authorKiziltunc, Emrullah
dc.contributor.authorYayla, Cagrı
dc.contributor.authorErtem, Ahmet Goktuğ
dc.contributor.authorGenc, Ahmet
dc.contributor.authorOztekin, Gulsum Meral Yılmaz
dc.contributor.authorGitmez, Mesut
dc.contributor.authorTuncay, Burcu
dc.contributor.authorCan, Veysi
dc.contributor.authorAri, Hasan
dc.contributor.authorTatar, Fatih Pasa
dc.contributor.authorGazi, Emine
dc.contributor.authorYeşildas, Cuma
dc.contributor.authorEr, Okan
dc.contributor.authorOzturk, Onder
dc.contributor.authorCandemir, Aytac
dc.contributor.authorKayikçioglu, Meral
dc.contributor.authorYavuzgil, Oguz
dc.contributor.authorMirzaoğlu, Cetin
dc.contributor.authorBakirci, Eftal Murat
dc.contributor.authorDegirmenci, Husnu
dc.contributor.authorBesli, Feyzullah
dc.contributor.authorInce, Orhan
dc.date.accessioned2026-10-18T20:28:26.039490895Z
dc.date.available2026-10-18T20:28:26.039490895Z
dc.date.issued2020
dc.description.abstractObjective: The TURKMI registry is designed to provide insight into the characteristics, management from symptom onset to hospital discharge, and outcome of patients with acute myocardial infarction (MI) in Turkey. We report the baseline and clinical characteristics of the TURKMI population. Methods: The TURKMI study is a nation-wide registry that was conducted in 50 centers capable of percutaneous coronary intervention selected from each EuroStat NUTS region in Turkey according to population sampling weight, prioritized by the number of hospitals in each region. All consecutive patients with acute MI admitted to coronary care units within 48 hours of symptom onset were prospectively enrolled during a predefined 2-week period between November 1, 2018 and November 16, 2018. Results: A total of 1930 consecutive patients (mean age, 62.0±13.2 years; 26.1% female) with a diagnosis of acute MI were prospectively enrolled. More than half of the patients were diagnosed with non-ST elevation MI (61.9%), and 38.1% were diagnosed with ST elevation MI. Coronary angiography was performed in 93.7% and, percutaneous coronary intervention was performed in 73.2% of the study population. Fibrinolytic therapy was administered to 13 patients (0.018%). Aspirin was prescribed in 99.3% of the patients, and 94% were on dual antiplatelet therapy at the time of discharge. Beta blockers were prescribed in 85.0%, anti-lipid drugs in 96.3%, angiotensin converting enzyme inhibitors in 58.4%, and angiotensin receptor blockers in 7.9%. Comparison with European countries revealed that TURKMI patients experienced MI at younger ages compared with patients in France, Switzerland, and the United Kingdom. The most prevalent risk factors in the TURKMI population were hypercholesterolemia (60.2%), hypertension (49.5%), smoking (48.8%), and diabetes (37.9%). Conclusion: The nation-wide TURKMI registry revealed that hypercholesterolemia, hypertension, and smoking were the most prevalent risk factors. TURKMI patients were younger compared with patients in European Countries. The TURKMI registry also confirmed that current treatment guidelines are largely adopted into clinical cardiology practice in Turkey in terms of antiplatelet, anti-ischemic, and anti-lipid therapy. ©Copyright 2020 by Turkish Society of Cardiology
dc.description.sponsorshipAcknowledgments: TURKMI is an investigator-initiated study sponsored by the Turkish Society of Cardiology that receives major funding from Astra-Zeneca Company for this project.
dc.identifier.doi10.14744/anatoljcardiol.2020.69696
dc.identifier.endpage53
dc.identifier.issn2149-2263
dc.identifier.issue1
dc.identifier.pmid32628144
dc.identifier.scopus2-s2.0-85088210952
dc.identifier.startpage43
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/13600
dc.identifier.volume24
dc.language.isoen
dc.publisherTurkish Society of Cardiology
dc.relation.ispartofAnatolian Journal of Cardiology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAcute myocardial infarction
dc.subjectCoronary artery disease
dc.subjectRegistry
dc.subjectTurkey
dc.subjectAdrenergic beta-Antagonists
dc.subjectAge Factors
dc.subjectAged
dc.subjectAngiotensin Receptor Antagonists
dc.subjectAngiotensin-Converting Enzyme Inhibitors
dc.subjectAspirin
dc.subjectCoronary Angiography
dc.subjectFemale
dc.subjectFibrinolytic Agents
dc.subjectHumans
dc.subjectHypercholesterolemia
dc.subjectHyperlipidemias
dc.subjectHypertension
dc.subjectIschemia
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Infarction
dc.subjectPercutaneous Coronary Intervention
dc.subjectPlatelet Aggregation Inhibitors
dc.subjectRegistries
dc.subjectRisk Factors
dc.subjectSmoking
dc.subjectacetylsalicylic acid
dc.subjectangiotensin receptor antagonist
dc.subjectantidiabetic agent
dc.subjectbeta adrenergic receptor blocking agent
dc.titleBaseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus25
rdl.oa.statusgold
rdl.source.indexSCOPUS